How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Uterine Fibroids

Select Clinical Trial

Protocol Number: ObsEva 16-OBE2109-008

Protocol Title: Phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Eligibility: Premenopausal women over 18, with menstrual cycles 21-40 days

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: 16-OBE2109-008 

Protocol Title: A Phase 3, multicentre, randomized, double-blind, placebocontrolled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with addback therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Eligibility: Premenopausal woman, Menstrual cycles ≥ 21 days and ≤ 40 days, presence of uterine fibroids, heavy menstrual blood loss

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Specialties
Clara McLean House
Make a Donation
News & Events